Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Newer, More Effective Drugs Needed to Treat Multidrug-resistant TB | |
|
| |
 |  |  | Comments |  |
 |  |
 |
 |
 |  |
 |
 Text  |
Study finds more research is needed for the use of newer drugs, a greater number of effective drugs, and a longer treatment regimen to improve survival of patients with multidrug resistant tuberculosis. This large study by a team of international researchers is published in this week's PLOS Medicine.
Global efforts to control tuberculosis are being challenged by the emergence of strains that are resistant to several antibiotics including isoniazid and rifampicin, the two most powerful, first-line (standard) anti-tuberculosis drugsso-called multidrug resistant tuberculosis (MDR-TB). The treatment of MDR-TB is lengthy, toxic, expensive, and has mostly resulted in poor outcomes for patients. Importantly, the optimal treatment regimens for MDR-TB have not been determined and, to date, there have been no randomized controlled trials of treatments for MDR-TB.
In this study, a large group of international researchers (the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB) combined data on outcomes of 9153 patients from 32 centers to find out more about the best way of treating MDR-TB. The researchers found that the use of certain drugs, the use of four or more effective drugs, and the duration of treatment were associated with successful patient outcomes.
The authors conclude: "This individual patient data meta-analysis of 9,153 patients suggests that treatment of MDR-TB should include a later generation quinolone, and ethionamide or prothionamide. In patients who have not received second-line drugs before, the optimal number of likely effective drugs appears to be at least four in the initial intensive phase, and at least three in the continuation phase. The duration of therapy associated with highest odds of success was 7-8.5 months for the initial intensive phase, and 25-27 months for total duration."
However, these findings should be interpreted with caution because of the limitations in the methods and type of data used in the study. The authors say: "In view of the serious limitations of these observational data, these findings should be considered to have highlighted several important questions for future clinical trials.
These questions include the role and choice of injectables (medications that have to be given by injection), the optimal duration of an injectable and total therapy, and the potential value of later generation quinolones as well as certain group 4 and group 5 drugs."
Source-Eurekalert
| |
|
|
More News on: Drug Toxicity, AIDS/HIV, Drugs Banned in India, Silicosis, Screening Tests for Tuberculosis
 Comment & Contribute
|
Related Links
Tuberculosis
TB spreads through the air when people with an active pulmonary tuberculosis infection cough, sneeze, shout or ...
Will Vitamin D Therapy Reduce TB Burden in India?
A new study that gives fresh insight into how vitamin D may affect the immune response was published in The Lancet, a leading medical ...
World Tuberculosis Day 2012 - 'Stopping TB in My Lifetime'
World Tuberculosis Day is an occasion to raise public awareness on a contagious disease that is treatable and preventable and yet has spread ...
Genome Sequencing & Social-Network Analysis Looks at TB Outbreak in a Community
Genome Sequencing & Social-Network Analysis maybe a tool to look at outbreak of communicable diseases in communities and may prove to be a useful ...
Drug Related News
New Drug Improves Sleep Disorder Among the Blind
Tasimelteon - a new experimental drug improves circadian rhythm sleep disorder that frequently affects people who are completely blind, finds study. ...
Australia Imposes Interim Ban on Synthetic Drugs
As part of a crackdown on the psychoactive substances which mimic the highs of their illegal counterparts, Australia imposed an interim ban on 19 ...
Osteoporosis Drug Stops Growth of Breast Cancer Cells
A drug used to treat osteoporosis has now been shown to stop the growth of breast cancer cells, finds study. The findings, ...
Increase in Heroin Availability Across Washington State
At the University of Washington's Alcohol and Drug Abuse Institute, new data indicates increases in heroin availability, abuse and deaths across the ...
Anti-Baldness Drug can Help Curb Men's Inclination Towards Alcohol
Researchers at George Washington University have found that an anti-baldness drug can help some people lose interest in drinking alcohol. ...
Patients Taking OTCs and NASIDs Have a Risk of Developing ADE
A new study claims that around one in every eight patients taking non-steroidal anti-inflammatory drugs or over the counter medication have a risk of ...
Medwonders Health Network
- Health News Index
- News Quick Links
 | News Central | | Health Watch | |
| Latest Health News | | Health In Focus | |
| News Category (500+) | | Breaking Health News | |
| Popular News | | Celebrating Life | |
| Health News and Press Release | | Medindia - Exclusive | |
| News Photo Gallery | | India Special | |
| News Video Gallery | | Lifestyle and Wellness | |
| News From Other Resources | |||
| News Categories: |
| » | You Need Insurance Answers Some States Help by Making It Simpler |
| » | Healthcare Cuts in Spain Poses Serious Risk to the Health of Its Citizens |
| » | Study Shows Irregular Heartbeat Risk in Endurance Skiers |
| » | Schools in Indiana Have to Decide Between Insurance for Part Timers or Reduce Working Hours |
| » | Brokers for Health Insurance Companies Draw Back from State Set Rates |
| More Insurance News | |
|
Ask an Expert
